6C1 Stock Chart & Stats
Currently, no data available
Please return soon. This page is being updated.
Bulls Say, Bears Say
Bulls Say
Strengthened Cash RunwayA materially larger cash balance and runway to H2 2028 provides durable funding to complete pivotal-enabling work for Varseta-M, supports planned combo/expansion trials, and materially reduces near-term financing pressure, allowing management to prioritize high-value development activities.
Regeneron Partnership ExpansionAn expanded collaboration with Regeneron increases non-dilutive optionality and commercial upside through potential nominations and milestone streams, preserves tiered royalty economics, and validates the Probody platform which strengthens long-term business development and licensing prospects.
Varseta‑M Clinical EfficacyRobust early efficacy (ORR 20–32%, ~7 months PFS) versus typical late-line standards supports a credible path to a registrational trial and potential differentiated product profile; this clinical signal underpins strategic prioritization and long-term commercial potential if safety/tolerability are managed.
Bears Say
High Cash BurnPersistent negative operating and free cash flow (~$80M TTM) means the company remains reliant on financing or milestone receipts to fund R&D beyond its current runway. Even with healthy cash today, sustained burn raises dilution risk or forces program trade-offs if milestones or partner funding are delayed.
Revenue Concentration And DeclineRevenue is lumpy and partnership-dependent; a near-80% Y/Y drop from completed collaborations highlights limited recurring product revenues and exposes the company to cash timing risk. This concentration makes operating budgets sensitive to milestone timing and new BD outcomes over the medium term.
Clinical Safety & Regulatory GatingPrincipal safety issue (Grade 3 diarrhea) and immature OS data create material execution and regulatory risk: tolerability will shape dose selection, registrational design, and labeling. Failure to reliably manage high-grade events could limit dose, reduce efficacy benefit, or complicate FDA interactions and approval timelines.
CytomX Therapeutics News
6C1 FAQ
What was CytomX Therapeutics Inc.’s price range in the past 12 months?
Currently, no data Available
What is CytomX Therapeutics Inc.’s market cap?
CytomX Therapeutics Inc.’s market cap is CHF671.06M.
When is CytomX Therapeutics Inc.’s upcoming earnings report date?
CytomX Therapeutics Inc.’s upcoming earnings report date is Aug 06, 2026 which is in 29 days.
How were CytomX Therapeutics Inc.’s earnings last quarter?
CytomX Therapeutics Inc. released its earnings results on May 07, 2026. The company reported -$0.081 earnings per share for the quarter, beating the consensus estimate of -$0.098 by $0.017.
Is CytomX Therapeutics Inc. overvalued?
According to Wall Street analysts CytomX Therapeutics Inc.’s price is currently Undervalued.
Does CytomX Therapeutics Inc. pay dividends?
CytomX Therapeutics Inc. does not currently pay dividends.
What is CytomX Therapeutics Inc.’s EPS estimate?
CytomX Therapeutics Inc.’s EPS estimate is -0.06.
How many shares outstanding does CytomX Therapeutics Inc. have?
Currently, no data Available
What happened to CytomX Therapeutics Inc.’s price movement after its last earnings report?
CytomX Therapeutics Inc. reported an EPS of -$0.081 in its last earnings report, beating expectations of -$0.098. Following the earnings report the stock price went same N/A.
Which hedge fund is a major shareholder of CytomX Therapeutics Inc.?
Currently, no hedge funds are holding shares in CH:6C1
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
CytomX Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
CHF9.52 (― Downside)
CHF9.52 (― Downside)
Insider Transactions
Sold Shares
Worth CHF4.0K over
the Last 3 Months
the Last 3 Months
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
62.02%
12-Months-Change
Fundamentals
Return on Equity
-36.61%
Trailing 12-Months
Asset Growth
264.84%
Trailing 12-Months
Company Description
CytomX Therapeutics Inc.
CytomX Therapeutics, Inc. is a United States-based biopharmaceutical company primarily focused on creating treatments for cancer. The company utilizes its proprietary Probody technology platform to engineer targeted antibody therapeutics for oncological applications. Its robust clinical pipeline includes several notable drug candidates. CX-2009, an antibody-drug conjugate (ADC) designed to target CD166, is currently in Phase II clinical trials for treating breast cancer. Another investigational therapy, CX-2029, has also reached Phase II trials, where it is being evaluated for various cancers such as squamous non-small cell lung cancer, head and neck squamous cell carcinoma, esophageal and gastro-esophageal junction cancers, and diffuse large B-cell lymphoma. Additionally, CytomX is progressing two CTLA-4 Probody therapeutics: BMS-986249, which is undergoing Phase I/II clinical trials for metastatic melanoma, and BMS-986288, in Phase I trials for solid tumors. Beyond these, the company is developing CX-2043, a conditionally activated ADC targeting the epithelial cell adhesion molecule, and CX-904, a conditionally activated epidermal growth factor receptor, both aimed at addressing solid tumor conditions. CytomX has forged strategic partnerships with leading pharmaceutical firms, including AbbVie Ireland Unlimited Company, Amgen, Inc., Bristol-Myers Squibb Company, ImmunoGen, Inc., Pfizer Inc., and Astellas Pharma Inc., to collaboratively advance its Probody therapeutics. The company was founded in 2008 and its main office is located in South San Francisco, California.
6C1 Company Deck
6C1 Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call emphasized substantial clinical progress and clear near-term development and regulatory plans for Varseta-M (robust ORR 20%–32% and ~7 months PFS, completed optimization enrollment, combination and expansion strategies), backed by a materially strengthened balance sheet (cash up ~152.9%) and runway into H2 2028. Key risks remain operational and clinical: a large year-over-year revenue decline driven by completed collaborations, modest increases in operating costs, and the need to confirm that Grade 3 diarrhea can be reliably managed in the full optimization cohort and over longer follow-up. Overall, the positive clinical momentum and strong cash position outweigh the near-term financial and clinical uncertainties.View all CH:6C1 earnings summaries6C1 Stock 12 Month Forecast
Average Price Target
$9.52
Lexicon Pharmaceuticals
―
Verastem
―
Arcturus Therapeutics
―
―
Bicycle Therapeutics
―
Options Prices
Currently, No data available
---